These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 27160750)
1. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence. Benson R; Mallick S; Julka PK; Rath GK J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750 [TBL] [Abstract][Full Text] [Related]
2. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Bozec A; Peyrade F; Milano G Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267 [TBL] [Abstract][Full Text] [Related]
3. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cohen RB Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225 [TBL] [Abstract][Full Text] [Related]
4. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865 [TBL] [Abstract][Full Text] [Related]
5. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer. Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Uribe P; Gonzalez S Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242 [TBL] [Abstract][Full Text] [Related]
8. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Lu H; Li X; Lu Y; Qiu S; Fan Z Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723 [TBL] [Abstract][Full Text] [Related]
9. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. Iberri DJ; Colevas AD Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236 [TBL] [Abstract][Full Text] [Related]
10. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029 [TBL] [Abstract][Full Text] [Related]
11. Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. Swick AD; Prabakaran PJ; Miller MC; Javaid AM; Fisher MM; Sampene E; Ong IM; Hu R; Iida M; Nickel KP; Bruce JY; Wheeler DL; Kimple RJ Mol Cancer Ther; 2017 Jul; 16(7):1257-1268. PubMed ID: 28446642 [TBL] [Abstract][Full Text] [Related]
12. EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex. Lei Y; Kansy BA; Li J; Cong L; Liu Y; Trivedi S; Wen H; Ting JP; Ouyang H; Ferris RL Oncogene; 2016 Sep; 35(36):4698-707. PubMed ID: 26876213 [TBL] [Abstract][Full Text] [Related]
13. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311 [TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck. Machiels JP; Schmitz S Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ; Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998 [TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796 [TBL] [Abstract][Full Text] [Related]
17. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139 [TBL] [Abstract][Full Text] [Related]
18. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Corvò R Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300 [TBL] [Abstract][Full Text] [Related]
19. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Pollock NI; Grandis JR Clin Cancer Res; 2015 Feb; 21(3):526-33. PubMed ID: 25424855 [TBL] [Abstract][Full Text] [Related]
20. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Burtness B Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]